



June 23, 2014

Company Name	3 - D Matrix, Ltd.
Address	3-2-4Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
TEL	+81 3 (3511) 3440

**[Delayed] Patent Granted for “Cardiac Tissue Regeneration”
with Self-Assembling Peptide Technology**

(This original disclosure in Japanese was released on June 20, 2014 at 15:30 (GMT+9))

The company hereby announces that a patent for application of self-assembling peptide technology to regeneration of cardiac tissue, filed by the company’s U.S. subsidiary, has been granted in Japan.

[Title of invention] Composition and Method for Cardiac Tissue Protection and Regeneration
[Patent Number] Japan Patent No. 5558104
[Patent Owner] 3-D Matrix, Inc.

This patent relates to protection and regeneration of cardiac tissue using self-assembling peptides. The process, which involves the introduction of self-assembling peptides to cardiac tissue areas injured due to an acute myocardial infarction, has been shown to be effective in improving heart conditions.

Myocardial cells have virtually no proliferation capability, and the function of tissue injured in an acute myocardial infarction steadily deteriorates without recovery. An approach at recovery based on regeneration therapy has raised expectations for treatment of the resulting necrotic tissue, and many studies toward practical application are in progress. This patent, which involves a process using self-assembling peptides, a scaffolding material for cells, to protect the cardiac tissue and also to promote tissue regeneration, shows a new therapeutic approach to improve cardiac function, and can be expected to contribute to acute myocardial infarction treatment.

The company will continue to promote research and development in fields of regenerative medicine using this patent. In this same field, research in the area of bone and skin regeneration is in progress, and efforts are also being expanded in the area of organ regeneration, including treatment of heart disease, to promote development of effective medical products that will lead to expansion of our corporate value.

This patent granted does not influence the earning forecast of the company at this moment.